Figure 1. SR4 and niclosamide inhibit proliferation of melanoma irrespective of BRAF/NRAS status.

(A) Chemical structures of SR4 and niclosamide. (B) Dose response curves and IC₅₀ values of the seven melanoma lines treated with SR4, niclosamide and vemurafenib. Cell viability was measured by Cell Titer Glo assay after 48 h. IC₅₀ values were calculated using GraphPad prism (n = 3). (C) Representative colony formation assays of melanoma cells following treatments with DMSO control or 1 μM each of SR4, niclosamide and vemurafenib. (D) Annexin V staining after treatment with SR4 (5 μM) and niclosamide (1 μM) for 48 h (mean ± SEM, n = 3). ^*P < 0.05 vs. DMSO control.